{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:42:44Z","timestamp":1777124564888,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014418","name":"Harbin medical university cancer hospital","doi-asserted-by":"crossref","award":["No. Nn10 PY 2017-03"],"award-info":[{"award-number":["No. Nn10 PY 2017-03"]}],"id":[{"id":"10.13039\/100014418","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28503-7","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T18:03:34Z","timestamp":1763921014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LRP12 promotes gastric cancer progression through AKT\/mTOR signaling and M2 macrophage-mediated immunosuppression"],"prefix":"10.1038","volume":"15","author":[{"given":"Yufei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MeiDing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"28503_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin, D., Thomas, A. & Teicher, B. A. Cancer treatments: Past, present, and future. Cancer Genet. 286\u2013287, 18\u201324. https:\/\/doi.org\/10.1016\/j.cancergen.2024.06.002 (2024).","journal-title":"Cancer Genet."},{"issue":"3","key":"28503_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"28503_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Association JGC","year":"2021","unstructured":"Association JGC Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 24 (1), 1\u201321. https:\/\/doi.org\/10.1007\/s10120-020-01042-y (2021).","journal-title":"Gastric Cancer"},{"issue":"8","key":"28503_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 22 (8), 1081\u20131092. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7 (2021).","journal-title":"Lancet Oncol."},{"issue":"5","key":"28503_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144 (5), 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"issue":"7467","key":"28503_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (7467), 346\u2013354. https:\/\/doi.org\/10.1038\/nature12626 (2013).","journal-title":"Nature"},{"issue":"11","key":"28503_CR7","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15 (11), e493\u2013503. https:\/\/doi.org\/10.1016\/S1470-2045(14)70263-3 (2014).","journal-title":"Lancet Oncol."},{"issue":"23","key":"28503_CR8","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-23-3523","volume":"30","author":"D Skubleny","year":"2024","unstructured":"Skubleny, D. et al. The tumor immune microenvironment drives survival outcomes and therapeutic response in an integrated molecular analysis of gastric adenocarcinoma. Clin. Cancer Res. 30 (23), 5385\u20135398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3523 (2024).","journal-title":"Clin. Cancer Res."},{"key":"28503_CR9","doi-asserted-by":"publisher","first-page":"216807","DOI":"10.1016\/j.canlet.2024.216807","volume":"593","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer. Cancer Lett. 593, 216807. https:\/\/doi.org\/10.1016\/j.canlet.2024.216807 (2024).","journal-title":"Cancer Lett."},{"issue":"19","key":"28503_CR10","doi-asserted-by":"publisher","first-page":"e2500136","DOI":"10.1002\/smll.202500136","volume":"21","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. SERPINE1 facilitates metastasis in gastric cancer through Anoikis resistance and tumor microenvironment remodeling. Small 21 (19), e2500136. https:\/\/doi.org\/10.1002\/smll.202500136 (2025).","journal-title":"Small"},{"issue":"1","key":"28503_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cercor\/bhq070","volume":"21","author":"S Schneider","year":"2011","unstructured":"Schneider, S., Gulacsi, A. & Hatten, M. E. Lrp12\/Mig13a reveals changing patterns of Preplate neuronal Polarity during corticogenesis that are absent in reeler mutant mice. Cereb. Cortex. 21 (1), 134\u2013144. https:\/\/doi.org\/10.1093\/cercor\/bhq070 (2011).","journal-title":"Cereb. Cortex"},{"key":"28503_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lfs.2016.01.049","volume":"155","author":"BK Robens","year":"2016","unstructured":"Robens, B. K. et al. Abundance of LRP12 C-rs9694676 allelic promoter variant in epilepsy-associated gangliogliomas. Life Sci. 155, 70\u201375. https:\/\/doi.org\/10.1016\/j.lfs.2016.01.049 (2016).","journal-title":"Life Sci."},{"key":"28503_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fpsyt.2010.00019","volume":"1","author":"AS Gibbons","year":"2010","unstructured":"Gibbons, A. S., Thomas, E. A., Scarr, E. & Dean, B. Low density lipoprotein Receptor-Related protein and Apolipoprotein E expression is altered in schizophrenia. Front. Psychiatry. 1, 19. https:\/\/doi.org\/10.3389\/fpsyt.2010.00019 (2010).","journal-title":"Front. Psychiatry"},{"issue":"2","key":"28503_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.onc.1202290","volume":"18","author":"J Qing","year":"1999","unstructured":"Qing, J., Wei, D., Maher, V. M. & McCormick, J. J. Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines. Oncogene 18 (2), 335\u2013342. https:\/\/doi.org\/10.1038\/sj.onc.1202290 (1999).","journal-title":"Oncogene"},{"issue":"14","key":"28503_CR15","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1038\/sj.onc.1207367","volume":"23","author":"C Garnis","year":"2004","unstructured":"Garnis, C., Coe, B. P., Zhang, L., Rosin, M. P. & Lam, W. L. Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas. Oncogene 23 (14), 2582\u20132586. https:\/\/doi.org\/10.1038\/sj.onc.1207367 (2004).","journal-title":"Oncogene"},{"issue":"10","key":"28503_CR16","doi-asserted-by":"publisher","first-page":"e11123","DOI":"10.1016\/j.heliyon.2022.e11123","volume":"8","author":"ES Deepak Shyl","year":"2022","unstructured":"Deepak Shyl, E. S., Malgija, B., Iniyan, A. M., Mahendran, R. & Prakash Vincent, S. G. Mining of transcriptome identifies CD109 and LRP12 as possible biomarkers and deregulation mechanism of T cell receptor pathway in acute myeloid leukemia. Heliyon 8 (10), e11123. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11123 (2022).","journal-title":"Heliyon"},{"issue":"1","key":"28503_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13073-018-0562-1","volume":"10","author":"S Grasse","year":"2018","unstructured":"Grasse, S. et al. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance. Genome Med. 10 (1), 55. https:\/\/doi.org\/10.1186\/s13073-018-0562-1 (2018).","journal-title":"Genome Med."},{"issue":"9","key":"28503_CR18","doi-asserted-by":"publisher","first-page":"e104249","DOI":"10.1371\/journal.pone.0104249","volume":"9","author":"N Bethge","year":"2014","unstructured":"Bethge, N. et al. A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma. PLoS One. 9 (9), e104249. https:\/\/doi.org\/10.1371\/journal.pone.0104249 (2014).","journal-title":"PLoS One"},{"issue":"6","key":"28503_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28 (6), 882\u2013883. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034 (2012).","journal-title":"Bioinformatics"},{"issue":"D1","key":"28503_CR20","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun, D. et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 49 (D1), D1420. https:\/\/doi.org\/10.1093\/nar\/gkaa1020 (2021). -1420D1430.","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"28503_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer. 1 (2), 235\u2013248. https:\/\/doi.org\/10.1038\/s43018-019-0018-6 (2020).","journal-title":"Nat. Cancer"},{"key":"28503_CR22","doi-asserted-by":"publisher","first-page":"110368","DOI":"10.1016\/j.intimp.2023.110368","volume":"120","author":"T Wang","year":"2023","unstructured":"Wang, T. et al. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. Int. Immunopharmacol. 120, 110368. https:\/\/doi.org\/10.1016\/j.intimp.2023.110368 (2023).","journal-title":"Int. Immunopharmacol."},{"issue":"D1","key":"28503_CR23","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53 (D1), D672. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025). -672D677.","journal-title":"Nucleic Acids Res."},{"issue":"15","key":"28503_CR24","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"BH Sohn","year":"2017","unstructured":"Sohn, B. H. et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin. Cancer Res. 23 (15), 4441\u20134449. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2211 (2017).","journal-title":"Clin. Cancer Res."},{"key":"28503_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu, L., Wei, J. & Liu, P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 85, 69\u201394. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.019 (2022).","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"28503_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.4049\/jimmunol.1601515","volume":"198","author":"E Vergadi","year":"2017","unstructured":"Vergadi, E., Ieronymaki, E., Lyroni, K., Vaporidi, K. & Tsatsanis, C. Akt signaling pathway in macrophage activation and M1\/M2 polarization. J. Immunol. 198 (3), 1006\u20131014. https:\/\/doi.org\/10.4049\/jimmunol.1601515 (2017).","journal-title":"J. Immunol."},{"key":"28503_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2019.03.015","volume":"452","author":"S Wang","year":"2019","unstructured":"Wang, S. et al. Metabolic reprogramming of macrophages during infections and cancer. Cancer Lett. 452, 14\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.015 (2019).","journal-title":"Cancer Lett."},{"issue":"4","key":"28503_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.immuni.2016.09.016","volume":"45","author":"SC Huang","year":"2016","unstructured":"Huang, S. C. et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 45 (4), 817\u2013830. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.016 (2016).","journal-title":"Immunity"},{"key":"28503_CR29","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/ncomms3834","volume":"4","author":"V Byles","year":"2013","unstructured":"Byles, V. et al. The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun. 4, 2834. https:\/\/doi.org\/10.1038\/ncomms3834 (2013).","journal-title":"Nat. Commun."},{"issue":"4","key":"28503_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2015.08.001","volume":"27","author":"AJ Covarrubias","year":"2015","unstructured":"Covarrubias, A. J., Aksoylar, H. I. & Horng, T. Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin Immunol. 27 (4), 286\u2013296. https:\/\/doi.org\/10.1016\/j.smim.2015.08.001 (2015).","journal-title":"Semin Immunol."},{"issue":"7655","key":"28503_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545 (7655), 495\u2013499. https:\/\/doi.org\/10.1038\/nature22396 (2017).","journal-title":"Nature"},{"issue":"17","key":"28503_CR32","doi-asserted-by":"publisher","first-page":"e37046","DOI":"10.1016\/j.heliyon.2024.e37046","volume":"10","author":"L Ou","year":"2024","unstructured":"Ou, L. et al. Helicobacter pylori infection facilitates cell migration and potentially impact clinical outcomes in gastric cancer. Heliyon 10 (17), e37046. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37046 (2024).","journal-title":"Heliyon"},{"key":"28503_CR33","doi-asserted-by":"publisher","unstructured":"Xue, G. et al. Integrated Akt\/PKB signaling in Immunomodulation and its potential role in cancer immunotherapy. J. Natl. Cancer Inst. 107 (7). https:\/\/doi.org\/10.1093\/jnci\/djv171 (2015).","DOI":"10.1093\/jnci\/djv171"},{"issue":"10","key":"28503_CR34","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R Inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (10), 1264\u20131272. https:\/\/doi.org\/10.1038\/nm.3337 (2013).","journal-title":"Nat. Med."},{"issue":"6","key":"28503_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro, K. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17 (6), 717\u2013726. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3 (2016).","journal-title":"Lancet Oncol."},{"issue":"3\u20134","key":"28503_CR36","doi-asserted-by":"publisher","first-page":"CBM240119","DOI":"10.3233\/CBM-240119","volume":"41","author":"AM Rasteh","year":"2024","unstructured":"Rasteh, A. M., Liu, H. & Wang, P. Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases. Cancer Biomark. 41 (3\u20134), CBM240119. https:\/\/doi.org\/10.3233\/CBM-240119 (2024).","journal-title":"Cancer Biomark."},{"issue":"1","key":"28503_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu, H., Li, Y., Karsidag, M., Tu, T. & Wang, P. Technical and biological biases in bulk transcriptomic data mining for cancer research. J. Cancer. 16 (1), 34\u201343. https:\/\/doi.org\/10.7150\/jca.100922 (2025).","journal-title":"J. Cancer"},{"issue":"1","key":"28503_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s12672-025-03067-0","volume":"16","author":"A Dong","year":"2025","unstructured":"Dong, A., Rasteh, A., Wang, P. & Liu, H. An in-silico pan-cancer bulk and single-cell profiling of transcription factors in protein autoubiquitination. Discov Oncol. 16 (1), 1245. https:\/\/doi.org\/10.1007\/s12672-025-03067-0 (2025).","journal-title":"Discov Oncol."},{"issue":"1","key":"28503_CR39","doi-asserted-by":"publisher","first-page":"e0314745","DOI":"10.1371\/journal.pone.0314745","volume":"20","author":"H Liu","year":"2025","unstructured":"Liu, H., Karsidag, M., Chhatwal, K., Wang, P. & Tang, T. Single-cell and bulk RNA sequencing analysis reveals CENPA as a potential biomarker and therapeutic target in cancers. PLoS One. 20 (1), e0314745. https:\/\/doi.org\/10.1371\/journal.pone.0314745 (2025).","journal-title":"PLoS One"},{"issue":"1","key":"28503_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10238-024-01538-2","volume":"25","author":"H Liu","year":"2024","unstructured":"Liu, H. & Wang, P. CRISPR screening and cell line IC50 data reveal novel key genes for Trametinib resistance. Clin. Exp. Med. 25 (1), 21. https:\/\/doi.org\/10.1007\/s10238-024-01538-2 (2024).","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"28503_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13020-024-01018-5","volume":"19","author":"Z Xu","year":"2024","unstructured":"Xu, Z., Rasteh, A. M., Dong, A., Wang, P. & Liu, H. Identification of molecular targets of hypericum perforatum in blood for major depressive disorder: a machine-learning Pharmacological study. Chin. Med. 19 (1), 141. https:\/\/doi.org\/10.1186\/s13020-024-01018-5 (2024).","journal-title":"Chin. Med."},{"issue":"20","key":"28503_CR42","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.3748\/wjg.v31.i20.106443","volume":"31","author":"HR Liu","year":"2025","unstructured":"Liu, H. R. Harnessing traditional medicine and biomarker-driven approaches to counteract trichostatin A-induced esophageal cancer progression. World J. Gastroenterol. 31 (20), 106443. https:\/\/doi.org\/10.3748\/wjg.v31.i20.106443 (2025).","journal-title":"World J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28503-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:07:36Z","timestamp":1777122456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28503"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28503-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study participants or their legal guardians provided signed informed consent forms. All the followed procedures were performed according to the ethical standards of the Human Subjects Responsibility Committee (institutions and countries), as well as the 1964 Helsinki Declaration and subsequent editions. This research was approved by Harbin Medical University Cancer Hospital Ethics Committee (Approval Number: 2019-164-R).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"45183"}}